ACI Submits Testimony Regarding Maryland’s House Bill-134

Today, ACI filed testimony on a Maryland House bill that proposes severe restrictions on the sale of e-cigarettes and vaping products. In our testimony, we find that HB-134, if enacted, would significantly harm consumer welfare and lead to avoidable negative health outcomes. The provisions in this legislation would be particularly harmful to Maryland’s consumers because […]

ACI Urges Maryland’s Legislature Not To Tax Online Advertising

The following is a statement by Krisztina Pusok, Directory of Policy and Research at ACI, regarding Maryland’s Digital Ad Tax: ACI strongly urges Maryland’s legislature not to overturn Governor Hogan’s veto of HB732 (Tobacco Tax, Sales and Use Tax, and Digital Advertising Gross Revenues Tax). The proposed digital ad tax, while vaguely worded, would have […]

ACI Files Testimony With the Maryland Senate

In ACI’s filed testimony today, we cite medical studies showing that vaping is 95% safer than combustible products and effective in weening smokers away from harmful combustible tobacco products. Yet, two Senate proposals attempt to restrict its access, classify vaping and tobacco products the same, and ban flavors that have been shown to help smoker […]

Maryland Consumers Should Demand Transparency from PBMs

Consumers in Maryland are facing rapidly rising prices at the pharmacy counter, but drug makers’ prices have roughly kept pace with inflation over the last few years. What gives? It turns out that pharmacy benefit managers (PBMs), a very small number of largely unregulated companies that administer the drug plans of more than 230 million […]

Center Maryland: Lawmakers in Annapolis Should Demand Greater Transparency from PBMs

If you’ve never heard of pharmacy benefits managers (PBMs), that’s the way they like it. While they administer drug plans for more than 230 million Americans, PBMs thrive on secrecy and a lack of transparency. Yet PBMs’ shady business practices deeply impact the lives of Marylanders by pushing up drug prices and limiting access to […]

Latest ConsumerGram: Lowering Drug Prices in Maryland Means Bringing Transparency to PBMs

Pharmacy Benefit Managers (PBMs) administer prescription drug plans for sponsors (e.g., employers and insurers), negotiate drug prices with manufacturers, and negotiate reimbursement terms with pharmacies. This ConsumerGram analyzes the structure, conduct and performance of the industry and finds that the lack of transparency in costs and prices leads to anticompetitive risks. The result can mean […]

Lower Rail Regulations Lowered Consumer Prices; So Don’t Undo These Benefits

Maryland residents have benefitted dramatically from smart, balanced freight rail regulations. This has made goods cheaper, created jobs and helped major economic hubs like the Port of Baltimore thrive. As activity increases at Maryland’s ports, it is vital for the state’s economy and consumers that the right rules are in place that will help freight […]

Coalition Letter Opposes Maryland Prescription Law

Today, a coalition of organizations sent a letter to Maryland Governor Hogan objecting to a bill that gives the State’s Attorney General additional authority over competitive generic drug pricing — drugs that are typically 80% lower than their name brand counterparts.  The letter is signed by American Consumer Institute, Consumer Action for a Strong Economy, FreedomWorks, Frontiers of Freedom, Independent Women’s […]

Anti-Consumer: Maryland House Bill 631 Would Raise Drug Prices

Senator Thomas M. Middleton, Chair Senator John C. Astle, Vice-Chair Senator Joanne C. Benson Senator Brian J. Feldman Senator Stephen S. Hershey, Jr. Senator J. B. Jennings Senator Katherine A. Klausmeier Senator James N. Mathias, Jr. Senator Nathaniel T. Oaks Senator Edward R. Reilly Senator James C. Rosapepe  Dear Senators:  The American Consumer Institute, a nonprofit educational […]